David Kavanagh

26.6k total citations · 2 hit papers
138 papers, 7.9k citations indexed

About

David Kavanagh is a scholar working on Immunology, Hematology and Nephrology. According to data from OpenAlex, David Kavanagh has authored 138 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Immunology, 57 papers in Hematology and 48 papers in Nephrology. Recurrent topics in David Kavanagh's work include Complement system in diseases (112 papers), Renal Diseases and Glomerulopathies (46 papers) and Blood groups and transfusion (38 papers). David Kavanagh is often cited by papers focused on Complement system in diseases (112 papers), Renal Diseases and Glomerulopathies (46 papers) and Blood groups and transfusion (38 papers). David Kavanagh collaborates with scholars based in United Kingdom, United States and Switzerland. David Kavanagh's co-authors include Anna Richards, Tim Goodship, Timothy H.J. Goodship, John P. Atkinson, Andrew P. Herbert, Edwin Wong, Vicky Brocklebank, M. Kathryn Liszewski, Paul N. Barlow and Marina Noris and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David Kavanagh

129 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

2006 531 citations Marina Noris, David Kavanagh et al. profile →
The ExAC browser: displaying reference data information from over 60 000 exomes

2016 452 citations David Kavanagh, Mark J. Daly et al. profile →

Peers

Countries citing papers authored by David Kavanagh

Since Specialization

Citations

This map shows the geographic impact of David Kavanagh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kavanagh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kavanagh more than expected).

Fields of papers citing papers by David Kavanagh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kavanagh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kavanagh. The network helps show where David Kavanagh may publish in the future.

Co-authorship network of co-authors of David Kavanagh

This figure shows the co-authorship network connecting the top 25 collaborators of David Kavanagh. A scholar is included among the top collaborators of David Kavanagh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kavanagh. David Kavanagh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-transplant Thrombotic Microangiopathy 2025 ·Journal of the American Society of Nephrology ·Anuja Java, Matthew A. Sparks, David Kavanagh	2
2	Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS 2025 ·Nephrology Dialysis Transplantation ·(unknown), Luke Vale, Yemi Oluboyede, (unknown), Andrew Bryant, Thomas Chadwick, (unknown), Sally Johnson, David Kavanagh, (unknown), Jan Lecouturier, (unknown), Edwin Wong, (unknown), Neil Sheerin	0
3	Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease 2025 ·Brain ·Sarah McGlasson, Kayleigh M. Reid, Anna Klingseisen, Bastien Rioux, Samuel D. Chauvin, Cathrine A. Miner, (unknown), (unknown), Bethany Geary, (unknown), Katrina Wood, Candice Roufosse, Colin Smith, David Kavanagh, Jonathan J. Miner, David Hunt	0
4	AAV-mHDM-FH: Safety and expression profile in two murine models of hyper-complement activation 2025 ·Immunobiology ·Grace Mallett, Isabel Y. Pappworth, Grant J. Logan, Ian E. Alexander, David Kavanagh, Kevin J. Marchbank	0
5	Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy 2024 ·Transplantation ·Caroline Duineveld, (unknown), (unknown), Nicole C. A. J. van de Kar, David Kavanagh, Jack F.M. Wetzels, Neil Sheerin	3
6	Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials 2024 ·Kidney Medicine ·Bradley P. Dixon, David Kavanagh, (unknown), Brigitte Adams, Hee Gyung Kang, Edward Wang, Katherine Garlo, Masayo Ogawa, Praveen K. Amancha, S. Chakravarty, Nils Heyne, Seong Heon Kim, Spero Cataland, Sung‐Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff‐Luett, (unknown), Larry A. Greenbaum	8
7	Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study 2023 ·Kidney International Reports ·Marina Vivarelli, Andrew S. Bomback, Matthias Meier, Yaqin Wang, Nicholas J.A. Webb, (unknown), Richard J. Smith, David Kavanagh	9
8	Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing 2022 ·Journal of Molecular Diagnostics ·Nikolai Tschernoster, Florian Erger, Patrick R. Walsh, Bairbre McNicholas, (unknown), Sandra Habbig, (unknown), Kat Folz‐Donahue, Christian Kukat, Mohammad R. Toliat, Christian Becker, Holger Thiele, David Kavanagh, Peter Nürnberg, Bodo B. Beck, Janine Altmüller	5
9	Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study 2022 ·BMJ Open ·(unknown), (unknown), Andrew Bryant, Sonya Carnell, Thomas Chadwick, Sally Johnson, David Kavanagh, Jan Lecouturier, Michal Malina, Eoin Moloney, Yemi Oluboyede, (unknown), Edwin Wong, (unknown), Neil Sheerin	5
10	A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in age-related macular degeneration 2022 ·Frontiers in Immunology ·Thomas M Hallam, (unknown), (unknown), Vicky Brocklebank, (unknown), Nikolaos Tzoumas, David Steel, Edwin Wong, (unknown), Andrew Lotery, Claire L. Harris, Kevin J. Marchbank, David Kavanagh	6
11	Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial 2022 ·Kidney International Reports ·Andrew S. Bomback, David Kavanagh, Marina Vivarelli, Matthias Meier, Yaqin Wang, Nicholas J.A. Webb, Angelo J. Trapani, Richard J. Smith	39
12	Complement factor I deficiency 2020 ·Neurology Neuroimmunology & Neuroinflammation ·Thomas Altmann, Megan Torvell, Stephen Owens, Dipayan Mitra, Neil Sheerin, B. Paul Morgan, David Kavanagh, Rob Forsyth	16
13	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy 2018 ·The Journal of Immunology ·(unknown), Matteo Breno, Nicolò Ghiringhelli Borsa, Fengxiao Bu, Véronique Frémeaux‐Bacchi, Daniel P. Gale, Lambertus P. van den Heuvel, David Kavanagh, Marina Noris, Sheila Pinto, Pavithra M. Rallapalli, Giuseppe Remuzzi, Santiago Rodrı́guez de Córdoba, (unknown), Richard J. Smith, Paula Vieira‐Martins, Elena B. Volokhina, Valerie Wilson, Timothy H.J. Goodship, Stephen J. Perkins	119
14	Thrombotic Microangiopathy in Inverted Formin 2–Mediated Renal Disease 2016 ·Journal of the American Society of Nephrology ·Rachel Challis, Troels Ring, Yaobo Xu, Edwin Wong, Oliver Floßmann, Ian S. Roberts, (unknown), (unknown), (unknown), Vicky Brocklebank, (unknown), Lisa Strain, Valerie Wilson, Katrina Wood, Kevin J. Marchbank, Mauro Santibanez‐Koref, Timothy H.J. Goodship, David Kavanagh	29
15	Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels 2015 ·Human Molecular Genetics ·David Kavanagh, (unknown), Elizabeth C. Schramm, Michael Triebwasser, E K Wagner, Soumya Raychaudhuri, Mark J. Daly, John P. Atkinson, Johanna M. Seddon	96
16	Autoantibodies to CD59, CD55, CD46 and CD35 are not associated with aHUS 2014 ·Molecular Immunology ·Sophie Ward, (unknown), (unknown), (unknown), Paula Bertram, Arthur Jackson, Catriona E. Barker, (unknown), David Kavanagh, Susan M. Lea, B. Paul Morgan, (unknown), (unknown), Kevin J. Marchbank	1
17	A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H 2008 ·The Journal of Immunology ·Christoph Q. Schmidt, Andrew P. Herbert, David Kavanagh, (unknown), (unknown), Bärbel S. Blaum, Malcolm Lyon, Dušan Uhrı́n, Paul N. Barlow	172
18	A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity 2008 ·The Journal of Immunology ·Anna M. Blom, (unknown), Matthew Edey, Martha Diaz-Torres, David Kavanagh, Anne Lampe, Judith A. Goodship, Lisa Strain, Nadeem Moghal, Mary L. McHugh, Carol Inward, Charles Tomson, Véronique Frémeaux‐Bacchi, Bruno O. Villoutreix, Timothy H.J. Goodship	48
19	Inherited Complement Regulatory Protein Deficiency Predisposes to Human Disease in Acute Injury and Chronic Inflammatory StatesThe Examples of Vascular Damage in Atypical Hemolytic Uremic Syndrome and Debris Accumulation in Age‐Related Macular Degeneration 2007 ·Advances in immunology ·Anna Richards, David Kavanagh, John P. Atkinson	60
20	Genetic and Functional Analyses of Membrane Cofactor Protein (CD46) Mutations in Atypical Hemolytic Uremic Syndrome 2006 ·Journal of the American Society of Nephrology ·(unknown), Elizabeth A. Moulton, David Kavanagh, Marie‐Agnès Dragon‐Durey, Jacques Blouin, Amy A. Caudy, Nadia Arzouk, (unknown), Maud François, Geneviève Guest, Jacques Pourrat, (unknown), Wolf H. Fridman, Chantal Loirat, John P. Atkinson	184

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact